Biotech Business - March 17, 2022
Ilya Pharma closes 8.5 million EUR funding round
Ilya Pharma has closed a 8.5 million EUR funding round where the EIC Fund participated and was joined by an international consortium of family offices and private investors. “I believe Ilya is at the forefront of science by developing what can be the next advancement in biologics, tissue regeneration and immunology. The management’s decision to […]
Biotech Business - February 24, 2022
Moderna to establish local commercial presence in the Nordics
The US biotech company, focusing om messenger RNA therapeutics and vaccines, has announced plans to expand its commercial footprint in Europe across six additional countries. The announcement reinforces Moderna’s commitment to Europe and vision as a global commercial enterprise, building on the recent announcement of expansion in the Asia-Pacific region, it states in a press […]
Acquisition - February 18, 2022
Xbrane pauses negotiations with expected acquirer of Primm Pharma
Xbrane Biopharma’s efforts to divest the subsidiary Primm Pharma continues although negotiations with the previously expected acquirer NewFaDem for the time being has been paused. Primm Pharma is a fully owned subsidiary of Xbrane specialized in long-acting injectables and developer of Spherotide, a long-acting triptorelin formulation candidate intended to be used in treatment of prostate […]
Biotech Business - February 15, 2022
Capitainer and Attana sign collaboration agreement
The two companies have signed an agreement with the goal of offering broader and more patient-centric blood sampling solutions for the Attana AVATM system starting with COVID-19 immune profiling. Since November 2021, Attana has been performing comparative studies of finger stick capillary blood samples simultaneously collected by both test tubes and Capitainer qDBS cards (quantitative […]
Agreement - February 8, 2022
Xbrane Biopharma enters agreement with Biogen
The two companies have entered into a commercialization and license agreement to develop, manufacture, and commercialize Xcimzane, a preclinical monoclonal antibody that is a proposed biosimilar referencing CIMZIA. CIMZIA’s primary indication is for rheumatoid arthritis in adults as well as axial spondylarthrosis, psoriasis and Crohn’s disease. In 2020 global sales of CIMZIA were 1.8 billion […]
Agreement - February 7, 2022
Aurealis Therapeutics enters into 139 million USD agreement with Xbiome
Swiss-Finnish Aurealis Therapeutics has entered into an exclusive license and collaboration agreement with Xbiome for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer (DFU), other chronic wounds, and inflammatory disease therapy AUP-16 in Greater China. Under the terms of the license and collaboration agreement, Xbiome acquires exclusive development and commercial rights for […]
